KELOWNA, BC / ACCESSWIRE / January 26, 2024 / Tryp Therapeutics, Inc. ('Tryp' or the 'Company') (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that in a strategic move to foster a robust market for their combined entity, Tryp and Exopharm Limited have been granted a pivotal 2 cent waiver by the Australian Securities Exchange ('ASX').

KELOWNA，BC/ACCESSWIRE/2024年1月26日/Tryp Therapeutics，Inc.（“Tryp”或“公司”）（CSE：Tryp）（OTCQB：TRYPF）是一家开创性的临床阶段生物技术公司，专注于开发静脉输注的裸盖菇素（裸盖菇素的活性代谢物），用于治疗未满足医疗需求的疾病，今天宣布，这是一项战略举措，旨在为其合并的实体培育一个强大的市场，Tryp和Exopharm Limited已被澳大利亚证券交易所（“ASX”）授予关键的2美分豁免。

This waiver is a fundamental step in enhancing the market dynamics and financial framework of the merged company..

该豁免是增强被合并公司的市场动态和财务框架的基本步骤。。

Consequently, Tryp has announced an amendment to its arrangement agreement with Exopharm Limited, originally dated December 8, 2023. This amendment is a direct result of the 2 cent waiver granted by the ASX and aligns with the recent trading history of Exopharm. It is important to note that these modifications are essential components of the waiver..

因此，TRIP已宣布对其与Exopharm Limited的安排协议进行修订，该协议最初日期为2023年12月8日。该修正案是澳大利亚证券交易所（ASX）2美分豁免的直接结果，与Exopharm最近的交易历史一致。重要的是要注意，这些修改是弃权的重要组成部分。。

Under the revised terms, Exopharm will acquire all issued and outstanding common shares of Tryp, in exchange for 3.616 ordinary shares of Exopharm for each Tryp share, a change from the previously stated ratio of 4.52. Additionally, there will be a consolidation of Exopharm shares before completing the transaction, adjusting from a 2:1 to a 2.5:1 consolidation ratio.

根据修订后的条款，Exopharm将收购Tryp的所有已发行和流通的普通股，以换取每个Tryp股份的3.616股Exopharm普通股，这与之前规定的4.52的比例有所不同。此外，在完成交易之前，将对Exopharm的股份进行合并，合并比例从2:1调整为2.5:1。

Pursuant to the Arrangement Agreement, holders of convertible securities of Tryp, including stock options, common share purchase warrants, secured convertible debentures and unsecured convertible notes will receive replacement securities of Exopharm having substantially similar economic terms in accordance with the rules of the ASX..

根据安排协议，Tryp可转换证券的持有人，包括股票期权、普通股认购权证、有担保的可转换债券和无担保的可转换票据，将根据澳大利亚证券交易所的规则获得具有实质相似经济条件的Exopharm替代证券。。

Detailed information about this arrangement will be provided in a management information circular by Tryp, which will be prepared, filed, and mailed to Tryp's securityholders in anticipation of an annual and special meeting to consider the Arrangement. It is crucial for all securityholders to review this circular once available, as it will contain important information pertinent to the arrangement and its implications..

关于这一安排的详细信息将由Tryp在管理信息通报中提供，该通报将编制、存档并邮寄给Tryp的证券持有人，以备召开年度和特别会议审议该安排。一旦获得本通知，所有证券持有人都必须对其进行审查，因为它将包含与该安排及其影响相关的重要信息。。

About Tryp Therapeutics

关于Tryp Therapeutics

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.

Tryp Therapeutics是一家临床阶段生物技术公司，专注于开发专有的新型制剂，用于管理psilocin并结合心理治疗，以治疗医疗需求未得到满足的疾病。TRIP的主要计划TRP-8803是静脉输注裸盖菇素（裸盖菇素的活性代谢产物）的专有配方，可缓解口服裸盖菇素的许多缺点，包括：显着减少迷幻状态的发作时间，控制迷幻体验的深度和持续时间，并将干预的总体持续时间缩短到商业上可行的时间范围。

The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%. The Company also recently announced commencement of patient dosing in a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and is preparing to initiate a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome.

该公司在佛罗里达大学完成了一项治疗暴饮暴食症的2a期临床试验，该试验表明暴饮暴食发作的平均减少率超过80%。该公司最近还宣布开始与密歇根大学合作进行治疗纤维肌痛的2a期临床试验，并准备与马萨诸塞州总医院合作启动2a期临床试验，用于治疗肠易激综合征患者的腹痛和内脏压痛。

Each of the studies is utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilize TRP-8803 (IV-infused psilocin), which has the potential to further improve efficacy, safety, and patient experience.

每项研究都利用TRP-8802（合成的口服裸盖菇素）来证明这些适应症的临床益处。如果证实有积极的临床反应，则预期随后的研究将利用TRP-8803（静脉输注的psilocin），这有可能进一步提高疗效，安全性和患者体验。

For more information, please visit www.tryptherapeutics.com..

有关更多信息，请访问www.tryptherapeutics.com。。

Investor & Media Contact

投资者和媒体联系人

Peter Molloy

彼得·莫洛伊

Chief Business Officer

首席商务官

Tryp Therapeutics Inc.

Tryp Therapeutics公司。

pmolloy@tryptherapeutics.com

pmolloy@tryptherapeutics.com

Forward-Looking Information

前瞻性信息

Certain information in this news release, including statements relating to the anticipated completion of the Arrangement and the holding of the annual and special meeting of Tryp's securityholders, constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as 'plans', 'targets', 'expects' or 'does not expect', 'is expected', 'an opportunity exists', 'is positioned', 'estimates', 'intends', 'assumes', 'anticipates' or 'does not anticipate' or 'believes', or variations of such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur' or 'be achieved'.

本新闻稿中的某些信息，包括与预期完成安排以及召开TRIP证券持有人年度和特别会议有关的声明，构成了前瞻性信息。在某些情况下，但不一定在所有情况下，可以通过使用前瞻性术语来识别前瞻性信息，例如“计划”，“目标”，“预期”或“不预期”，“预期”，“机会存在”，“定位”，“估计”，“打算”，“假设”，“预期”或“不预期”或“相信”，或此类词语和短语的变体，或说明某些行动、事件或结果“可能”、“可能”、“会”、“可能”、“会”或“将要采取”、“发生”或“将要实现”。

In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events..

此外，任何涉及未来事件或情况的预期、预测或其他特征的陈述都包含前瞻性信息。包含前瞻性信息的报表不是历史事实，而是管理层对未来事件的期望、估计和预测。。

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the 'Risk Factors' section of Tryp's final prospectus available at www.sedar.com.

前瞻性信息必然基于一些意见、假设和估计，尽管截至本新闻发布之日，TRIP认为这些意见、假设和估计是合理的，但它们受到已知和未知风险、不确定性、假设和其他因素的影响，这些因素可能会导致实际结果、活动水平，业绩或成就与此类前瞻性信息明示或暗示的业绩或成就存在重大差异，包括但不限于可在www.sedar.com上查阅的Tryp最终招股说明书“风险因素”部分中更详细描述的因素。

These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law..

这些因素并不代表可能影响TRIP的因素的完整列表；但是，应仔细考虑这些因素。无法保证此类估计和假设将被证明是正确的。本新闻稿中包含的前瞻性声明是在本新闻稿发布之日做出的，Tryp明确否认有义务更新或更改包含任何前瞻性信息或其背后的因素或假设的声明，无论是由于新信息、未来事件还是其他原因，除非法律要求。。

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

加拿大证券交易所及其监管服务提供商均未对本公告的充分性或准确性进行审查或承担责任。

SOURCE: Tryp Therapeutics

来源：Tryp Therapeutics

View the original press release on accesswire.com

在accesswire.com上查看原始新闻稿